CARNEGIE MELLON UNIVERSITY

FluidForm Bio Achieves Breakthrough in Vascularized Tissue Engineering for Diabetes Treatment

a month ago

• FluidForm Bio has developed an advanced FRESH 3D bioprinting technique using sacrificial gelatin microparticles that maintains cell viability five times deeper than traditional methods, addressing a critical limitation in tissue engineering. • The company recently strengthened its intellectual property with USPTO Patent No. 12,215,202 B2, protecting core innovations in their bioprinting platform that enables clinical-grade manufacturing of functional human tissue. • FluidForm's lead program focuses on type 1 diabetes treatment through subcutaneous implantation of bioprinted insulin-producing beta cells, offering a less invasive alternative with improved retrievability and reduced surgical risks.

Novel Spinal Cord Stimulation Shows Promise in Treating Spinal Muscular Atrophy

4 months ago

• A groundbreaking pilot study demonstrates that spinal cord implants delivering low-level electrical stimulation helped three adults with spinal muscular atrophy regain muscle function and mobility. • Participants showed significant improvements in walking distance, gait length, and standing ability, with one patient achieving a threefold increase in step length during the month-long trial. • The benefits persisted temporarily even after device deactivation, suggesting potential lasting effects, though the experimental implants were removed after the short-term study.

AI-Powered Histological Analysis Shows Promise in Celiac Disease Diagnosis

6 months ago

• A new AI model analyzes digital pathology images of duodenal biopsies to quantify histological features relevant to celiac disease, such as intraepithelial lymphocytes and villous height. • The AI model demonstrates high accuracy in identifying and classifying different cell types in H&E-stained tissue samples, comparable to expert gastrointestinal pathologists. • Model-derived histological features correlate with modified Marsh scores, indicating the potential for AI to assist in the objective assessment of celiac disease severity. • This AI-driven approach could enhance diagnostic accuracy, reduce inter-observer variability, and improve the efficiency of celiac disease diagnosis in clinical settings.

Rice University's Bioelectronic Implant Targets Diabetes and Obesity with $34.9 Million Grant

8 months ago

• Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence. • ROGUE will house cells that produce therapies in response to the patient’s needs, offering a cost-effective alternative to frequent injections of biologics like GLP-1 RAs. • The implantable device will use closed-loop bioelectronics to monitor and adjust drug production, requiring only weekly recharging via a wearable device. • Clinical trials are planned to begin in the fifth year of the six-year project, aiming for rapid and cost-effective deployment via a minimally invasive outpatient procedure.